Lilly’s Name For Headache Treatment Moves Forward
The U.S. Food and Drug Administration has conditionally accepted the intended brand name of a prospective headache treatment from Indianapolis-based Eli Lilly and Co. (NYSE: LLY). Emgality, which recently showed positive results in a massive, late-stage study, is under development to fight episodic cluster headaches.
Lilly Bio-Medicines President Christi Shaw says "often confused with migraine, cluster headache is a neurological disease that has been characterized as ‘beyond excruciating’ by those who live with it. We are proud to present full results of this data, which represents potential hope for a resilient community of people struggling to prevent episodic cluster headache."
The results are detailed here.